BioWorld

Aug. 8, 2006

View Archived Issues

Cabrellis' $27.5M Series A To Fund Three SCLC Trials

A Conforma Therapeutics Corp. spinout, barely three months old, closed a $27.5 million Series A financing to cover Phase II trials of its only product, Calsed, to treat small-cell lung cancer. (BioWorld Today) Read More

BioCryst, FDA Agree On SPA For Fodosine In Blood Cancer

Read More

New Analysis Shows ESC State Funding Not Enough

Read More

Nanoemulsion Platform Gets $30M Financing For NanoBio

Read More

Clinic Roundup

Read More

Other News To Note

Read More